Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung

Exclusion Criteria

• •Participation in another clinical study in the previous month
• •Severe concomitant disease which may have an impact on the study participation
• •Hypersensitivity against Ectoin
• •Myocardial infarction or apoplexy within the last year
• •Uncontrolled hypertension: systolic blood pressure \>200 mmHg or diastolic pressure \>120 mmHg
• •Known aortic aneurysm
• •Other respiratory diseases (e.g. cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, allergic alveolitis, tuberculosis, etc.)
• •Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit)
• •on investigators decision